Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies

• Published in: Cancer medicine (Malden, MA) Vol. 7; no. 8; pp. 4132 - 4145
• Main Authors: Radocha, Jakub, Maisnar, Vladimír, Pour, Luděk, Špička, Ivan, Minařík, Jiři, Szeligová, Lenka, Pavlíček, Petr, Jungová, Alexandra, Krejčí, Marta, Pika, Tomáš, Straub, Jan, Brožová, Lucie, Stejskal, Lukáš, Heindorfer, Adriana, Jindra, Pavel, Kessler, Petr, Mikula, Peter, Sýkora, Michal, Wróbel, Marek, Jarkovský, Jiří, Hájek, Roman
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.08.2018; John Wiley and Sons Inc
• Subjects: Adult; Aged; Aged, 80 and over; Cancer Prevention; Clinical medicine; Cytogenetics; Czech Myeloma Group Registry; Czech Republic - epidemiology; Diagnosis; Female; Humans; Male; Middle Aged; monoclonal gammopathies; Multiple myeloma; Multiple Myeloma - diagnosis; Multiple Myeloma - epidemiology; Neoplasm Staging; Original Research; overall survival; Paraproteinemias - diagnosis; Paraproteinemias - epidemiology; Patients; Practice Patterns, Physicians; real‐world; Registries; Retrospective Studies; Risk Assessment; Risk Factors; risk stratification; Survival; Survival Analysis; Czech Republic; overall survival; real-world; multiple myeloma; risk stratification; Czech Myeloma Group Registry; monoclonal gammopathies
• ISSN: 2045-7634; 2045-7634
• DOI: 10.1002/cam4.1620

This study used data from the Czech Myeloma Group Registry of Monoclonal Gammopathies to validate the International Myeloma Working Group (IMWG) and revised International Staging System (R‐ISS) indices for risk stratification in patients with multiple myeloma (MM) in clinical practice. Patients were included if they had symptomatic MM, complete data allowing R‐ISS and IMWG staging (including cytogenetic information regarding t(4;14), t(14;16), and del(17p)), and key parameters for treatment evaluation. Median overall survival (OS) in included patients (n = 550) was 47.7 (95% CI: 39.5‐55.9) and 46.2 (95% CI: 38.9‐53.5) months from diagnosis and initiation of first‐line therapy, respectively. Patients categorized as higher vs lower risk had reduced survival; median OS from diagnosis was 35.4 (95% CI: 30.5‐40.3) vs 58.3 (95% CI: 53.8‐62.9) months in high‐risk vs other patients (IMWG; P = .001) and 34.1 (95% CI: 30.2‐38.0) vs 47.2 (95% CI: 43.4‐51.0) months in Stage III vs Stage II patients (R‐ISS; P < .001). In conclusion, IMWG and R‐ISS risk stratification indices are applicable to patients with MM in a real‐world setting. We have successfully validated R‐ISS myeloma prognostic score on real‐life unselected population. The system can be broadly applicable outside clinical trials.